Insulin-sensitizer drugs, such as thiazolidinediones, and anti-inflammatory drugs, such as inhibitors of cyclooxygenase (COX-2), have been shown to have protective effects in experimental models of HD (111, 112). Here, INS is linked to Huntington disease.